The Organizing Committee of the San Antonio Breast Cancer Symposium® welcomes you to the Best of SABCS® Houston 2020 to be held on February 29, 2020 in collaboration with the Texas Society of Clinical Oncology (TxSCO).
The SABCS®, now in its 42nd year, is the premier conference for basic, translational and clinical cancer research professionals. It is well known for presenting the latest breast cancer data from all over the world.
The Best of SABCS® allows professionals who unable to travel to San Antonio, as well as those who seek a concise critical review, the opportunity to hear expert multidisciplinary faculty review and place in context conference highlights, as originally presented at SABCS® 2019, in a half-day program. Attendees will learn the current advances in breast cancer research that are changing clinical practice for the benefit of patients as well as exciting translational science soon to impact breast cancer care in the near future.
We would like to extend recognition and thanks to the supporters of the Best of SABCS® for understanding the importance of this education and making it possible to organize this very valuable educational activity.
We encourage and look forward to your attendance; please register early to secure a place.
These regional symposia are directed to academic and community physicians, medical residents and fellows training in oncology subspecialties, physician assistants, nurse practitioners and basic/translational researchers involved in breast cancer. Specialties include medical, surgical, gynecologic, and radiation oncology, as well as other pertinent healthcare professionals involved in breast cancer medicine.
The Long School of Medicine designates this live activity up to a maximum of 4.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• Identify factors that predispose individuals and increase the risk of developing breast cancer
• Describe prognostic and predictive molecular signatures and biomarkers that can identify the most appropriate treatment strategies for individuals with breast cancer.
• Discuss scientific advances from the laboratory that have great potential to translate into increased knowledge of breast cancer biology and pathogenesis.
• Review new results from clinical trials in all aspects of breast cancer care presented during oral, poster and educational sessions at the annual San Antonio Breast Cancer Symposium®.
• Discuss on results of evidence from preclinical research and clinical trials that support the rational combinations of traditional and newer pharmacologic interventions, with a focus on novel therapeutics and resistance mechanisms.
• Develop appropriate individualized treatment strategies for those patients who would benefit from new treatments in all the major subtypes of breast cancer and also focus on reversing resistance to commonly used therapies.
Education to improve physician understanding of the latest trial data, guidelines, and applications in clinical practice has been identified as a vehicle for closing the knowledge gap and helping to improve patient outcomes [Christian 2006]. This proposed CME symposium will address the above gaps in clinical practice/knowledge between what is known and what healthcare practitioners wish to better understand regarding the screening, diagnosis, and management of patient with BC. In addition, it will focus on identified research/presentations from SABCS® 2019 that cover these issues, including results of BC research, facilitating the rapid translation of new knowledge into better care for breast cancer patients and addressing issues such as axillary management in primary BC, human epidermal growth factor receptor 2 (HER2), cell cycle regulation with CDK inhibitors, genomic heterogeneity, and proteomic analysis of BC.
|Contact No. :||+1 443-370-2698
|Registration Type||Last Date||Price|
|Early Fee||26 Feb,2020||USD 75.00|
|TxSCO Member Fee||28 Feb,2020||USD 25.00|
|Fellow, Resident, Nurse Practitioner Fee||28 Feb,2020||USD 25.00|
|Industry Attendees Early Fee||26 Feb,2020||USD 100.00|